E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
The US FDA approval introduces a new adjuvant treatment option for stage III dMMR colon cancer, with Roche stating that Tecentriq combined with chemotherapy could become the new standard of care.
imphoenix82
Zydus and MSN are the first companies to launch a generic version of Adempas (riociguat) in the US market.
imphoenix82
The US FDA approval follows Lupin’s recent launch of Formoflo-G metered-dose inhaler for chronic obstructive pulmonary disease (COPD) in India
imphoenix82
Akums’ new moisturisation portfolio spans everyday hydration, intensive moisturisation, nourishment, barrier-focused care and targeted skincare, providing brands with multiple concepts within the category.
imphoenix82
A case report by Redcliffe Labs researchers has highlighted the role of genetic testing in antenatal diagnosis of rare inherited disorders that may not be detectable through routine prenatal ultrasound alone.
imphoenix82
Philips will support Charnock Hospitals in deploying critical care technologies and other integrated, digitally enabled healthcare solutions across its existing and upcoming facilities.
imphoenix82
The FDA approval brings TUKYSA into the frontline maintenance setting, offering patients with HER2-positive metastatic breast cancer a chemotherapy-free option following initial treatment that may help delay disease progression.
imphoenix82
Glenmark Pharmaceuticals’ US subsidiary, Glenmark Therapeutics Inc., USA, has introduced adapalene gel 0.1%, an over-the-counter (OTC) acne treatment, in new pump packs. Adapalene 0.1% is an FDA-approved topical OTC retinoid indicated for the treatment of acne in people aged 12 years and older. According to Glenmark, adapalene gel 0.1% contains the same active ingredient as […]
imphoenix82
Stryker’s Mako 4 SmartRobotics combines patient-specific planning, robotic technology and haptic guidance in a single system across three applications.
imphoenix82
In the first phase, JOSH Teams to be rolled out across 55 districts in 11 states to strengthen youth-led community mobilisation for TB Mukt Bharat.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
